Conferences

Viewing 1-20 of 11872 articles

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting

Clarity to Present COBRA and CLARIFY Abstracts at Two World-Leading Conferences

SUO 2024: Biomarkers and Clinical Predictors in RCC

SUO 2024: Update on Neoadjuvant Therapy Trials in RCC

SUO 2024: Sexual Dysfunction and Radical Cystectomy

SUO 2024: Joseph A Smith, Jr. Mentorship Award Lecture

SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting

SUO 2024: ABLE-32: A Randomized, Controlled, Phase IIIB Clinical Trial of Nadofarogene Firadenovec-vcng versus Observation in Patients with Intermediate-risk, Non-muscle Invasive Bladder Cancer

SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radical Prostatectomy

SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radiotherapy

SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Focal Ablation

SUO 2024: Sustainability in Prostate Cancer Care

SUO 2024: Biology of Cancer Metastases

SUO 2024: Game Changing Team Science

SUO 2024: Preventing and Managing Long Term Complications of Radical Cystectomy

SUO 2024: Exploratory Analysis of Post-treatment Outcomes in Patients with Bacillus Calmette-Guerin-unresponsive High-risk, Non-muscle Invasive Bladder Cancer Who Experienced Non-Response to Pembrolizumab Monotherapy in KEYNOTE-057

SUO 2024: Setting the Stage: Our Current Options for BCG Unresponsive NMIBC

SUO 2024: Are We Missing Aggressive Cancer with PSA Screening Alone? Biochemical Recurrence After Radical Prostatectomy: Evidence from the STHLM3 Trial

SUO 2024: Telehealth and Cancer: Public Policy and Future Directions

1
2
3
4
5
6
7
8
9
10